

## United States Patent and Trademark Office

10

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/825,593	04/16/2004	Nicholas Barden	028622-0130	7794
FOLEY AND LARDNER LLP SUITE 500			EXAMINER	
			PAK, MICHAEL D	
3000 K STREET NW WASHINGTON, DC 20007			ART UNIT	PAPER NUMBER
	,		1646	
SHORTENED STATUTOR	Y PERIOD OF RESPONSE	MAIL DATE	DELIVERY MODE	
31 D	DAYS	03/01/2007	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.

	Application No.	Applicant(s)				
	10/825,593	BARDEN ET AL.				
Office Action Summary	Examiner	Art Unit				
·	Michael Pak	1646				
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address				
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA  - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period w  - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tirr vill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	I. lely filed the mailing date of this communication. C (35 U.S.C. § 133).				
Status	·					
1) Responsive to communication(s) filed on  2a) This action is <b>FINAL</b> . 2b) This  3) Since this application is in condition for allowar closed in accordance with the practice under E	action is non-final. nce except for formal matters, pro					
Disposition of Claims						
4) ☐ Claim(s) 1-22,24-30,32-34 and 36-56 is/are per 4a) Of the above claim(s) is/are withdraw 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) is/are rejected. 7) ☐ Claim(s) is/are objected to. 8) ☐ Claim(s) 1-22,24-30, 32-34, 36-56 are subject	vn from consideration.	irement.				
9) The specification is objected to by the Examiner 10) The drawing(s) filed on is/are: a) acce		Examiner.				
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correction 11) The oath or declaration is objected to by the Ex	on is required if the drawing(s) is obj	ected to. See 37 CFR 1.121(d).				
Priority under 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of:  1. Certified copies of the priority documents 2. Certified copies of the priority documents 3. Copies of the certified copies of the prior application from the International Bureau * See the attached detailed Office action for a list of	s have been received. s have been received in Application ity documents have been received (PCT Rule 17.2(a)).	on No In this National Stage				
Attachment(s)  1) Notice of References Cited (PTO-892)  2) Notice of Draftsperson's Patent Drawing Review (PTO-948)  3) Information Disclosure Statement(s) (PTO/SB/08)	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal P	te				
Paper No(s)/Mail Date	6)  Other:					

Application/Control Number: 10/825,593

Art Unit: 1646

## **DETAILED ACTION**

## Election/Restrictions

- 1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
- I. Claims 1-10, 13, 20-22, 46 drawn to an isolated and purified polynucleotide, an expression vector, a host cell, a method for producing a polypeptide, classified in Class 435, subclass 69.1.
- II. Claims 14, 20-22, 46, drawn to a polypeptide, classified in Class 530, subclass 350.
- III. Claim 15-16, 20-22, 46, drawn to a purified antibody, classified in Class 435, subclass 387.1.
- IV. Claim 17, 20-22, 46, drawn to an aptamer, classified in Class 536, subclass 24.3.
- V. Claims 19-22, 46, drawn to a primer pair, classified in Class 536, subclass 24.33.
- VI. Claim 24, drawn to a method of diagnosing disorder with protein level, classified in Class 436, subclass 2.
- VII. Claim 25-27, 54-56, drawn to a method of diagnosing disorder with gene sequence, classified in Class 435, subclass 6.
  - VIII. Claims 28-29, 32, 34 drawn to a composition, Class 514, subclass 44.
  - IX. Claims 28-29, drawn to a composition, Class 514, subclass 2.
  - X. Claims 28-29, drawn to a composition, Class 424, subclass 130.1.

Page 2

XI. Claims 30, drawn to a method of treating disease with nucleic acid, Class 514, subclass 44.

XII. Claims 33, drawn to a pharmaceutical composition comprising a compound, classification could not be determined because no structure is provided.

XIII. Claims 36-45, drawn to a method of treating disease with a modulator, classification could not be determined because no common structure is provided.

XIV. Claims 47-49, drawn to a method of identifying a compound, Class 435, subclass 7.1.

XV. Claims 50-53, drawn to a method of producing an identified compound, classification could not be determined because no common structure is provided.

XVI. Claims 11-12, drawn to a transgenic organism, Class 800, subclass 2.

The inventions are distinct, each from the other because of the following reasons.

The products of any one of the inventions I-V, VIII-X, XII and XVI, are distinct each from the other, because they are drawn to products having materially different structures and functions.

Inventions VI-VII, XI and XIII-XV are distinct, each from the other, because they are drawn to processes having materially different process steps, which are practiced for materially different purposes.

The products of inventions I-V, VIII-X, XII and XVI, and the process of invention VI-VII, XI and XIII-XV are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for

using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the alternative inventions I-V, VIII-X, XII and XVI can be used in the alternative processs of Group VI-VII, XI and XIII-XV.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their different classifications and recognized divergent subject matter, and the search required for any one of inventions I-VIII is not required for any other invention I-VIII, restriction for examination purposes as indicated is proper.

Part II: Markush Group of claim limitations

Furthermore, restriction to one of the following inventions is required under 35 USC 121:

The inventions as they pertain to one mutation position member of claims 1, 15 and 26.

This is a further requirement for restriction into separately patentable groups.

Applicant must elect one member in order to be fully responsive. Because each disorder requires a unique search of the literature databases and undue search burden would be imposed on the examiner if all of the members were examined on one patent application.

Furthermore, restriction to one of the following inventions is required under 35 USC 121:

The inventions as they pertain to one compound member of claims 37-42 and 52-53.

This is a further requirement for restriction into separately patentable groups.

Applicant must elect one member in order to be fully responsive. Because each disorder requires a unique search of the the literature databases and undue search burden would be imposed on the examiner if all of the members were examined on one patent application.

Furthermore, restriction to one of the following inventions is required under 35 USC 121:

The inventions as they pertain to one disorder of claims 42-45.

This is a further requirement for restriction into separately patentable groups.

Applicant must elect one member in order to be fully responsive. Because each disorder requires a unique search of the literature databases and undue search burden would be imposed on the examiner if all of the members were examined on one patent application.

Applicant is advised that the response to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 C.F.R. §1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one

claim remaining in the application. Any amendment of inventorship must be accompanied by a diligently-filed petition under 37 C.F.R. § 1.48(b) and by the fee required under 37 C.F.R. § 1.17(h).

2. The examiner has required restriction between product and process claims. Where applicant elects claims directed to the product, and the product claims are subsequently found allowable, withdrawn process claims that depend from or otherwise require all the limitations of the allowable product claim will be considered for rejoinder. All claims directed a nonelected process invention must require all the limitations of an allowable product claim for that process invention to be rejoined.

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103 and 112. Until all claims to the elected product are found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowable product claim will not be rejoined. See MPEP § 821.04(b). Additionally, in order to retain the right to rejoinder in accordance with the above policy, applicant is advised that the process claims should be amended during prosecution to require the limitations of the product claims. Failure to do so may result in a loss of the right to rejoinder. Further, note that the prohibition against double

Application/Control Number: 10/825,593 Page 7

**Art Unit: 1646** 

patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement

is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

3. Any inquiry concerning this communication or earlier communications from the

examiner should be directed to Michael Pak whose telephone number is 571-272-0879.

The examiner can normally be reached on 8:00 - 2:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, Gary Nickol can be reached on 571-272-083535. The fax phone number for

the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the

Patent Application Information Retrieval (PAIR) system. Status information for

published applications may be obtained from either Private PAIR or Public PAIR.

Status information for unpublished applications is available through Private PAIR only.

For more information about the PAIR system, see http://pair-direct.uspto.gov. Should

you have questions on access to the Private PAIR system, contact the Electronic

Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a

USPTO Customer Service Representative or access to the automated information

system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Michael Pak

**Primary Patent Examiner** 

Hichard PAK

Art Unit 1646

5 January 2006

1. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Michael Pak whose telephone number is 571-272-0879. The examiner can normally be reached on 8:00 - 2:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Nickol can be reached on 571-272-083535. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Michael Pak Primary Patent Examiner Art Unit 1646 19 June 2006 Application/Control Number: 10/825,593

Art Unit: 1646

Page 9